See more : EIH Associated Hotels Limited (EIHAHOTELS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of 908 Devices Inc. (MASS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 908 Devices Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Mudanjiang Hengfeng Paper Co.,Ltd (600356.SS) Income Statement Analysis – Financial Results
- Kuehne + Nagel International AG (0QMW.L) Income Statement Analysis – Financial Results
- Hang Yick Holdings Company Limited (1894.HK) Income Statement Analysis – Financial Results
- Trifecta Gold Ltd. (TRRFF) Income Statement Analysis – Financial Results
- Nestlé (Malaysia) Berhad (4707.KL) Income Statement Analysis – Financial Results
908 Devices Inc. (MASS)
About 908 Devices Inc.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 50.23M | 46.85M | 42.21M | 26.89M | 17.97M | 22.05M |
| Cost of Revenue | 24.91M | 20.83M | 18.97M | 11.97M | 9.83M | 9.66M |
| Gross Profit | 25.32M | 26.02M | 23.23M | 14.92M | 8.14M | 12.39M |
| Gross Profit Ratio | 50.41% | 55.54% | 55.05% | 55.49% | 45.31% | 56.19% |
| Research & Development | 21.90M | 17.53M | 13.07M | 8.24M | 8.99M | 9.53M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 46.18M | 43.88M | 32.24M | 12.50M | 11.29M | 9.30M |
| Other Expenses | 0.00 | 1.82M | 386.00K | -6.03M | 301.00K | 50.00K |
| Operating Expenses | 68.08M | 61.41M | 45.30M | 20.74M | 20.29M | 18.83M |
| Cost & Expenses | 92.99M | 82.23M | 64.28M | 32.71M | 30.12M | 28.49M |
| Interest Income | 6.48M | 2.03M | 500.00K | 100.00K | 200.00K | 0.00 |
| Interest Expense | 201.00K | 129.00K | 486.00K | 976.00K | 1.53M | 1.15M |
| Depreciation & Amortization | 2.38M | 1.61M | 925.00K | 831.00K | 900.00K | 896.00K |
| EBITDA | -34.03M | -31.82M | -20.94M | -11.01M | -10.94M | -5.49M |
| EBITDA Ratio | -67.74% | -75.52% | -51.37% | -44.04% | -60.89% | -24.91% |
| Operating Income | -42.76M | -35.38M | -22.07M | -5.82M | -12.14M | -6.44M |
| Operating Income Ratio | -85.13% | -75.52% | -52.29% | -21.62% | -67.57% | -29.20% |
| Total Other Income/Expenses | 6.15M | 1.82M | -100.00K | -7.00M | -1.23M | -1.10M |
| Income Before Tax | -36.61M | -33.56M | -22.17M | -12.82M | -13.37M | -7.54M |
| Income Before Tax Ratio | -72.89% | -71.64% | -52.53% | -47.66% | -74.41% | -34.17% |
| Income Tax Expense | -211.00K | -1.82M | -53.00K | -5.88M | 1.83M | 50.00K |
| Net Income | -36.40M | -31.74M | -22.12M | -6.94M | -15.20M | -7.54M |
| Net Income Ratio | -72.47% | -67.75% | -52.40% | -25.79% | -84.60% | -34.17% |
| EPS | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| EPS Diluted | -1.13 | -1.01 | -0.79 | -0.25 | -0.58 | -0.40 |
| Weighted Avg Shares Out | 32.21M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
| Weighted Avg Shares Out (Dil) | 32.24M | 31.49M | 27.96M | 27.27M | 26.20M | 18.98M |
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago.
908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024. "We delivered solid execution on a multitude of fronts in the quarter,...
Earnings Preview: 908 Devices Inc. (MASS) Q2 Earnings Expected to Decline
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Visible Mineralization Allows Masivo to Extend Drilling Depth on Hole For The Third Time
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2024) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) ("Masivo" or the "Company") is pleased to announce that after extending the hole target depth three times it has successfully completed drilling 456.05 Feet at hole...
908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors...
908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors
BOSTON--(BUSINESS WIRE)-- #hazmat--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an enhanced quantification package for its XplorIR handheld gas and vapor analyzer. With this software update, the device, part of...
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector...
908 Devices to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences. 2024 Leerink Partners Healthcare Crossroads Conference, Austin, Texas Fireside chat on...
Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 133.7% in 908 Devices (MASS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
908 Devices (MASS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for...
Source: https://incomestatements.info
Category: Stock Reports